Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5127 - Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)

Date

10 Sep 2017

Session

Poster display session

Presenters

Thomas Powles

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

T. Powles1, R.J. Motzer2, D.J. George3, E. Jonasch4, S. Pal5, N.M. Tannir6, S. Signoretti7, T.H. Mai8, C. Scheffold9, E. Wang10, D.T. Aftab11, B. Escudier12, T.K. Choueiri13

Author affiliations

  • 1 Centre For Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ - London/GB
  • 2 Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 3 Duke Cancer Institute, Duke University Medical Center, 27710 - Durham/US
  • 4 Department Of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 5 Department Of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte/US
  • 6 Department Of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston/US
  • 7 Pathology, Brigham and Women’s Hospital, Boston/US
  • 8 Pharmacometrics, Ann Arbor Pharmacometrics Groups, Ann Arbor/US
  • 9 Clinical Development, Exelixis, Inc, South San Francisco/US
  • 10 Translational Medicine, Exelixis, Inc, South San Francisco/US
  • 11 Executive Administration, Exelixis, Inc., 94080 - South San Francisco/US
  • 12 Medical Oncology, Gustave-Roussy, 94800 - Villejuif  /FR
  • 13 Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
More

Resources

Abstract 5127

Background

C inhibits tyrosine kinases that promote oncogenesis and resistance to antiangiogenic therapy in RCC, including MET, AXL, and VEGF receptors. In the phase 3 METEOR trial (NCT01865747), C significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) vs E in patients (pts) with advanced RCC after prior VEGFR-targeted therapy (Choueiri, Lancet Oncol 2016). The current study evaluated outcomes based on plasma biomarker levels.

Methods

Plasma samples collected at baseline and during treatment from 621 of 658 randomized pts were analyzed for HGF, MET, Gas6, AXL, VEGF, VEGFR2, CA9, and IL-8 by ELISA (Assay Gate, Ijamsville, MD). PFS and OS were analyzed based on low vs high (< median vs ≥ median) biomarker levels at baseline.

Results

Analyses of PFS and OS based on baseline biomarker levels showed improvement with C vs E (hazard ratio

Conclusions

PFS and OS improved with C irrespective of baseline plasma biomarker levels in previously treated pts with advanced RCC vs E. However, low baseline levels of a subset of biomarkers were associated with better clinical outcomes with C.

Clinical trial identification

NCT01865747

Legal entity responsible for the study

Exelixis, Inc.

Funding

Exelixis, Inc.

Disclosure

T. Powles: Consultant/advisory: Exelexis Novartis GSK; Research funding: Exelexis Novartis GSK Genetech. R.J. Motzer: Consulting Role: Exelixis, Eisai, Pfizer, Novartis; Research Funding (institution): Exelixis, Eisai, Bristol-Myers Squib, Pfizer, Novartis. D.J. George: Ad Board: Bristol-Myers Squib, Exelixis, Genentech/Roche, Novartis, Pfizer; Corporate-sponsored Research: Bristol-Myers Squib, Exelixis, Genentech/Roche, Novartis, Pfizer Other: Acceleron – IDMC. E. Jonasch: Research funding: Exelixis, Pfizer, Novartis; Honoraria: Bristol-Myers Squib, Eisai, Exelixis, Novartis, Pfizer. S. Pal: Honoraria: Novartis, Medivation and Astellas Pharma; Consulting fees: Pfizer, Novartis, Aveo, Genentech, Exelixis, Bristol-Myers Squib, Astellas and GSK. N.M. Tannir: Ad Board: Bristol-Myers Squib, Exelixis, Nektar, Novartis, Pfizer, Argos, Calithera; Corproate-sponsored Research: Bristol-Myers Squib, Exelixis, Epizyme, Novartis, Miranti. S. Signoretti: Consulting Role: AstraZeneca, Merck; Research Funding (institution): AstraZeneca, Exelixis Patents/Intellectual Property: Biogenex. C. Scheffold: Employee: Exelixis. E. Wang, D.T. Aftab: Employee: Exelixis, Inc. B. Escudier: Honorarium: Bristol-Myers Squib, Novartis, Pfizer, Ipsen, Roche, Bayer, Calithera, Acceleron, EUSA, Eisai. T.K. Choueiri: Research Funding: Pfizer, GSK, Novartis, Bristol-Myers Squib, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton; Consulting Role: Pfizer, GSK, Novartis, Merck, Bayer, Eisai, Roche, Prometheus Labs Inc, Bristol-Myers Squib, Foundation Medicine Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.